By Rep. Pete Stark (D-Calif.)
These remarks were transcribed by The RPM Report from Ways & Means/Health Subcommittee Chairman Pete Stark’s remarks to the Stanford...
The Stark Truth About Health Care
A blunt assessment of the health care sector by one of the key legislators in the new Congress. Remarks by Rep. Pete Stark during the Stanford Washington Policy Research conference.
More from Market Access
• By
The health technology assessment institute, NICE, said the price BioMarin was asking for Brineura was too high, even though its appraisal committee applied a cost-effectiveness threshold ten times higher than usual.
• By
Vertex and Biogen are working with the Dutch government to ensure access for eligible patients.
• By
The arrangement, which implies a behind the scenes negotiated discount, may signal a trend toward less price transparency in foreign markets as manufacturers parry Trump’s Most Favored Nation price demands.
• By
AbbVie didn’t get everything it sought from a citizen petition but may still have the upper hand over smaller rivals after FDA gives makers of animal-derived thyroid medications a year to seek approval. If the agency removes compounded products, it could face more pricing pushback.
More from Pink Sheet
• By
New guidance from the National Pharmaceutical Regulatory Agency responds to the medicines shortages crisis that Malaysia experienced a few years ago.
• By
Vertex and Biogen are working with the Dutch government to ensure access for eligible patients.
• By
Aurobindo is confident its planned Lannett acquisition will meet US FTC standards after an attempt to acquire Sandoz assets was nixed in 2020. The deal also could widen Aurobindo’s US manufacturing presence.